CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
Tumor-infiltrating cytotoxic T lymphocytes (TILs), including CD8 TILs, have been associated with favorable clinical outcomes in multiple tumor types. Tumor-infiltrating CD8 T cells and major histocompatibility complex (MHC) class I expression in urothelial carcinoma (UC) have not been previously reported. Most immune responses are mediated by local cytotoxic lymphocytes (CD8 T cells), which can eradicate tumor cells by recognizing tumor-associated antigens presented by MHC class I molecules. Here we analyzed the presence of intratumoral CD8 T cells, the expression of MHC class I antigen, and the expression of the NY-ESO-1 tumor antigen in UC samples and correlated our findings with clinical outcome. Immunohistochemical staining for intratumoral CD8 T cells in tissue samples from 69 patients with UC showed that patients with advanced UC (pT2, pT3, or pT4) and higher numbers of CD8 TILs within the tumor (> or =8) had better disease-free survival (P < 0.001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC.
Sharma
Padmanee
P
Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. padsharma@mdanderson.org
Shen
Yu
Y
Wen
Sijin
S
Yamada
Sachiko
S
Jungbluth
Achim A
AA
Gnjatic
Sacha
S
Bajorin
Dean F
DF
Reuter
Victor E
VE
Herr
Harry
H
Old
Lloyd J
LJ
Sato
Eiichi
E
D000951:Antigens, Neoplasm / Q000096:biosynthesis; D016827:CD8 Antigens / Q000096:biosynthesis*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D002277:Carcinoma / Q000097:blood* / Q000276:immunology / Q000401:mortality*; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D005260:Female; D005805:Genes, MHC Class I; D006801:Humans; D007150:Immunohistochemistry; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism*; D008297:Male; D009132:Muscles / Q000378:metabolism*; D011379:Prognosis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000401:mortality*
D000951:Antigens, Neoplasm; D016827:CD8 Antigens